Clinical Trial Update: BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study [Phase 1]

View source ↗

Summary

Phase 1 trial updating BrUOG 302 using BYL719 (alpelisib) with capecitabine and radiation for rectal cancer; trial status terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• BYL719 (alpelisib)
• Capecitabine (capecitabine)

Snippet

Sponsor: howard safran | Conditions: Rectal Cancer | Phase 1 | Status: TERMINATED | Results posted: 2021-03-12